Xarelto's Comparative Efficacy To Warfarin, Pradaxa Will Be Focus At FDA Panel Review
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA will ask its Cardiovascular and Renal Drugs Advisory Committee whether Bayer/Johnson & Johnson's anticoagulant rivaroxaban must be shown to be "as effective" as warfarin and/or Boehringer Ingelheim's dabigatran at preventing stroke in atrial fibrillation patients.